Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma.
Ludwig
H
H
Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Vienna, Austria.
Strasser-Weippl
K
K
Schreder
M
M
Zojer
N
N
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D007166:Immunosuppressive Agents; D013792:Thalidomide; D003907:Dexamethasone; D004317:Doxorubicin; D008558:Melphalan; D011241:Prednisone